ResMed Inc. (NYSE:RMD) Director Witte Jan De Sells 796 Shares

ResMed Inc. (NYSE:RMD) Director Witte Jan De sold 796 shares of the company’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $248.81, for a total value of $198,052.76. Following the completion of the transaction, the director now owns 6,723 shares in the company, valued at $1,672,749.63. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

ResMed Stock Down 0.6 %

RMD stock traded down $1.53 during midday trading on Thursday, hitting $233.91. The company’s stock had a trading volume of 270,407 shares, compared to its average volume of 1,045,089. The firm’s 50-day moving average is $243.30 and its 200-day moving average is $223.37. The company has a current ratio of 2.92, a quick ratio of 1.91 and a debt-to-equity ratio of 0.13. ResMed Inc. has a 12 month low of $147.31 and a 12 month high of $260.49. The company has a market cap of $34.34 billion, a PE ratio of 31.18, a P/E/G ratio of 1.81 and a beta of 0.69.

ResMed (NYSE:RMD) last released its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $2.20 EPS for the quarter, beating the consensus estimate of $2.03 by $0.17. ResMed had a return on equity of 25.53% and a net margin of 23.15%. The company had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.19 billion. During the same period last year, the firm posted $1.64 earnings per share. ResMed’s revenue was up 11.1% compared to the same quarter last year. On average, equities research analysts forecast that ResMed Inc. will post 9.22 earnings per share for the current fiscal year.

ResMed Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 12th. Shareholders of record on Thursday, November 7th will be paid a dividend of $0.53 per share. The ex-dividend date is Thursday, November 7th. This represents a $2.12 dividend on an annualized basis and a yield of 0.91%. ResMed’s dividend payout ratio is presently 28.08%.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Ashton Thomas Securities LLC bought a new position in shares of ResMed in the third quarter worth about $34,000. OFI Invest Asset Management purchased a new position in ResMed during the second quarter valued at approximately $32,000. Versant Capital Management Inc boosted its position in shares of ResMed by 196.7% in the second quarter. Versant Capital Management Inc now owns 181 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 120 shares during the period. Financial Connections Group Inc. purchased a new stake in shares of ResMed in the second quarter worth $37,000. Finally, Blue Trust Inc. raised its position in shares of ResMed by 182.7% during the 2nd quarter. Blue Trust Inc. now owns 212 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 137 shares during the period. Institutional investors own 54.98% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on RMD shares. Needham & Company LLC reaffirmed a “hold” rating on shares of ResMed in a report on Friday, October 25th. KeyCorp increased their price objective on ResMed from $251.00 to $266.00 and gave the company an “overweight” rating in a research note on Friday, October 25th. StockNews.com raised shares of ResMed from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th. Wolfe Research reissued an “underperform” rating and set a $180.00 price target on shares of ResMed in a research report on Wednesday, September 18th. Finally, Robert W. Baird boosted their price objective on shares of ResMed from $280.00 to $283.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $225.70.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.